Tirzepatide and kidney function in obesity

Obesity is one of the most common drivers of progressive kidney decline. Excess body weight raises blood pressure, promotes insulin resistance, and generates systemic inflammation^[1] -- all three of which damage the glomeruli that filter blood. Researchers at the Federico II University Hospital in Naples set out to ask whether tirzepatide, a drug already shown to produce substantial weight loss and metabolic improvement, also moves kidney markers in the right direction in a real-world outpatient setting^[2].

The study design

The study, published in the Journal of Translational Medicine on 16 July 2026 (PMID 42464302), enrolled 36 adults with either overweight (BMI 27.0 kg/m2 or above with at least one weight-related comorbidity) or obesity (BMI 30.0 kg/m2 or above). All participants received weekly subcutaneous tirzepatide injections, starting at 2.5 mg and titrated to 5 mg, over three months^[2]. The design was retrospective and observational. There was no comparator arm.

Alongside standard kidney markers, the team collected body weight, BMI, waist circumference, fasting glucose, HbA1c, insulin, HOMA-IR (a proxy for insulin resistance), and high-sensitivity C-reactive protein (hs-CRP, a marker of systemic inflammation).

What the results showed

After three months, every tracked outcome moved in the expected direction (all p less than 0.001 or p = 0.002 for HbA1c). Serum creatinine fell significantly and estimated glomerular filtration rate (eGFR) rose significantly^[2]. Body weight, BMI, waist circumference, fasting glucose, HbA1c, insulin, HOMA-IR and hs-CRP also improved across the cohort.

The most directly relevant finding for kidney researchers was the regression analysis. Changes in BMI emerged as the main independent predictor of the change in eGFR, accounting for approximately 19.4% of its variance^[2]. The authors interpret this as evidence that weight loss itself, rather than a direct pharmacological effect on the kidney, is the primary mechanism.

Why eGFR and creatinine matter

eGFR is the standard clinical measure of how well the kidneys are clearing waste from the blood. A value of 60 mL/min/1.73m2 or above is generally considered within the normal range; values below 60, sustained over three months or longer, are used to define chronic kidney disease (CKD) across five stages of declining function^[1]. Creatinine, a breakdown product of muscle metabolism, rises as kidney clearance falls, so a drop in creatinine alongside a rise in eGFR points in the same direction.

In people with obesity, the connection between weight and kidney function runs through several overlapping mechanisms: haemodynamic stress on the glomeruli from higher cardiac output, insulin resistance that promotes sodium retention and raises blood pressure, and pro-inflammatory cytokines that disrupt tubular function. A drug that reduces body weight, improves insulin sensitivity and lowers hs-CRP addresses all three simultaneously.

How tirzepatide works and what that implies

Tirzepatide acts on two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor^[3]. GLP-1 receptor agonists are already established in the kidney-disease literature -- semaglutide, for example, is the subject of a dedicated kidney outcomes trial (FLOW) that demonstrated a 24% reduction in the composite of major kidney events. Tirzepatide's dual mechanism adds GIP signalling, which contributes to greater weight reduction than GLP-1 alone and may carry additional metabolic effects that the current study was not powered to separate.

The Mounjaro prescribing information notes that no dose adjustment is needed for patients with renal impairment because renal clearance does not affect tirzepatide pharmacokinetics^[3]. It does flag, however, that healthcare providers should monitor kidney function when gastrointestinal adverse effects (nausea, vomiting, diarrhoea) are severe, since dehydration from those effects can precipitate acute kidney injury.

What the study does not tell us

Three months is a short window. Meaningful kidney outcomes research typically tracks eGFR slope over one to five years. The 36-participant sample means the confidence intervals on the regression coefficient are wide, and the absence of a control group means there is no way to separate the effect of tirzepatide from the effect of any concurrent dietary or lifestyle changes. The cohort also included participants across a range of baseline kidney function; stratified analyses by CKD stage are not reported.

None of this makes the findings uninteresting. They add a real-world data point to a line of inquiry that is already supported by larger mechanistic and trial evidence in the GLP-1 class. They do not, however, establish that tirzepatide should be considered a kidney-protective treatment in the same way that the FLOW trial established semaglutide's profile.

What to watch next

Eli Lilly has a dedicated kidney outcomes trial for tirzepatide (SURPASS-CVOT and related follow-on studies) and the investigational arm of SURPASS-K, which is tracking eGFR change in people with type 2 diabetes and CKD. Pending those readouts, the Galasso 2026 data provide preliminary direction but not the kind of hard-outcomes evidence that would change clinical guidelines. Readers interested in how regulatory bodies assess tirzepatide for metabolic conditions can follow the drug's EPAR and prescribing-information updates, which are the primary records of what is and is not an approved indication.

This article is for educational purposes only and does not constitute medical advice. Readers should consult a qualified healthcare provider before making any decisions about treatment.